Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer Nivolumab Evaluation With BEvacizumab And pacliTaxel (NEWBEAT) study (WJOG9917B)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Bevacizumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms NEWBEAT
- 29 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2018 Status changed from not yet recruiting to recruiting.